GeNeuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical tr…
Biotechnology
CH, Plan-les-Ouates [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared GeNeuro SA (GNRO.PA) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 309,544.72 | 17,984.00 | 1,150.99 | 682.09 | 924.39 | 0.00 | 27.8709 | 41.04 | -0.6659 | -17.6405 | -0.06 | -0.08 | 6.5943 | - - | |
| Maximum | - - | - - | - - | 39,973,011.00 | 881,933.00 | 85,592.00 | 99,050.00 | 262,089.00 | 0.02 | 1,336.3467 | 2,849.43 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | |
| Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -233.7460 | -132.82 | -101.7758 | -1,444.7800 | -1.06 | -12.64 | 0.1256 | - - | |
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.